Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
14
×
clinical trials
14
×
eli lilly
14
×
indiana blog main
indiana top stories
14
×
life sciences
national blog main
boston blog main
fda
boston top stories
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
san francisco top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
amgen
cancer
bristol-myers squibb
startups
teva pharmaceutical
abbvie
cancer immunotherapy
deals
glaxosmithkline
merck
What
bio
drug
roundup
fda
approval
companies
new
won
eli
migraine
class
drugs
lilly
medicines
news
week
approved
biotech
black
days
decades
developed
diabetes
diamond’s
gets
giant
growing
life
nash
pain
pharmaceutical
rnai
science
starts
abandoning
acute
addresses
ago
alliance
alzheimer’s
Language
unset
Current search:
biotech
×
" indiana top stories "
×
" clinical trials "
×
" eli lilly "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines